• Financial performance: NephroPlus posted 24% revenue growth, 31% adjusted EBITDA growth, and 42% PAT growth year-on-year, with EBITDA margins expanding by 120 basis points to nearly 23%.
• International revenue mix: International markets now account for 45% of total revenue and drove a 9% increase in revenue per treatment, benefiting from higher price points in the Philippines ($110) and Uzbekistan ($60) compared to India ($22).
• Clinic expansion targets: The company aims to add 40 to 50 clinics annually in India and 12 to 15 clinics via acquisitions in the Philippines, while also building new footprints in Saudi Arabia and Kazakhstan.
• Credit loss provisions: With government payers making accounts receivable structural, expected credit loss (ECL) provisioning remained within the expected 2% to 2.5% range, coming in at 2.4% of revenue for the quarter.